Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:05 ET | Source: Bitterroot Bio

Bitterroot Bio to Present Anti-CD47 Research at American Heart Association Annual Scientific Session 2025

PALO ALTO, Calif. and NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the...
June 02, 2025 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease

-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- PALO ALTO, Calif. and NEEDHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Bitterroot...
March 17, 2025 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio to Present Detailed Results from Phase 1 Study of BRB-002 at American College of Cardiology Annual Scientific Session 2025

PALO ALTO, Calif. and NEEDHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the...
January 08, 2025 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

BRB-002 was safe at all doses tested, with no SAEs reportedPhase 2 proof-of-concept study in patients with established atherosclerosis is expected to initiate in 1H 2025 PALO ALTO, Calif. and...
October 29, 2024 07:00 ET | Source: Bitterroot Bio

Bitterroot Bio Completes Enrollment in Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

PALO ALTO, Calif. and NEEDHAM, Mass. and MELBOURNE, Australia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today...
June 04, 2024 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary

PALO ALTO, Calif. and NEEDHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of...
April 29, 2024 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers

PALO ALTO, Calif. and MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the...
February 26, 2024 19:00 ET | Source: Bitterroot Bio

Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology

PALO ALTO, Calif., and ZHUHAI, China, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and...
October 30, 2023 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio to Present Preclinical Research at American Heart Association Conference

PALO ALTO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present...
June 07, 2023 08:00 ET | Source: Bitterroot Bio

Bitterroot Bio Launches Out of Stealth with $145 Million Series A Financing to Develop Transformative Medicines in Cardio-immunology

Founders, Executive Team, and Advisors are recognized scientific and clinical pioneers in the fields of immunology and cardiology Series A financing co-led by ARCH Venture Partners and Deerfield...